Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644516 | 1.00 | KDM4E (0.49) | KDM4ERAB9ANPC1NFE2L2L3MBTL1 | |
| SCHEMBL26643563 | 1.00 | KDM4E (0.49) | KDM4ERAB9ANPC1NFE2L2L3MBTL1 | |
| SCHEMBL21397879 | 0.84 | RAB9A (0.57) | KDM4ERAB9ANPC1L3MBTL1NPSR1 | |
| SCHEMBL11602459 | 0.84 | RAB9A (0.57) | KDM4ERAB9ANPC1L3MBTL1NPSR1 | |
| SCHEMBL14960439 | 0.78 | RAB9A (0.52) | KDM4ERAB9ANPC1L3MBTL1NPSR1 | |
| SCHEMBL1227091 | 0.75 | CTH (0.54) | KDM4ERAB9ANPC1L3MBTL1NPSR1 | |
| SCHEMBL22342539 | 0.75 | CTH (0.51) | KDM4ERAB9ANPC1L3MBTL1NPSR1 | |
| SCHEMBL22342569 | 0.75 | CTH (0.51) | KDM4ERAB9ANPC1L3MBTL1NPSR1 | |
| SCHEMBL29987412 | 0.75 | CTH (0.51) | KDM4ERAB9ANPC1L3MBTL1NPSR1 | |
| SCHEMBL77564 | 0.75 | CTH (0.54) | KDM4ERAB9ANPC1L3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522607-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | KDM4E 1412/4885RAB9A 2957/4885NPC1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.